Key result
Bosentan improves symptoms, exercise capacity, hemodynamics, and clinical outcomes in severe pulmonary hypertension.
Why the study?
Does bosentan improve symptoms and outcomes in patients with severe pulmonary hypertension?
Population
Patients with severe pulmonary hypertension
Design
Review
Loading...
May support bosentan consideration in severe PH; leaves open randomized confirmation of outcome benefits.
Does bosentan improve symptoms and outcomes in patients with severe pulmonary hypertension?
Bosentan is an effective oral dual endothelin receptor antagonist that improves clinical, hemodynamic, and echocardiographic parameters in patients with severe pulmonary hypertension.
A 2002 study conducted a review in Pulmonary Arterial Hypertension. Bosentan was evaluated. Bosentan therapy improves symptoms, exercise capacity, hemodynamics, echocardiographic parameters, and outcomes in patients with severe pulmonary hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: